Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $4 to $6.
AstraZeneca’s Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease
AstraZeneca Plc (NASDAQ: AZN)